Bank of America’s Theriva Biologics TOVX Stock Holding History

Bank of America’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,139	Closed	-$6.54K	–	6828
2025 Q4	$6.54K	Buy	31,139 +31,058	+38,343%	+$9.18K	﹤0.01%	6238
2025 Q3	$32	Buy	81 +7	+9%	+$3	﹤0.01%	8101
2025 Q2	$32	Buy	74 +33	+80%	+$27	﹤0.01%	8180
2025 Q1	$45	Buy	41 +21	+105%	+$29	﹤0.01%	8002
2024 Q4	$35	Buy	20 +11	+122%	+$16	﹤0.01%	7927
2024 Q3	$12	Buy	9 +3	+50%	+$15	﹤0.01%	8033
2024 Q2	$34	Buy	+6	New	+$52	﹤0.01%	7916
2024 Q1	–	Hold	0	–	–	–	7622
2023 Q4	–	Hold	0	–	–	–	7888
2023 Q3	–	Hold	0	–	–	–	7698
2023 Q2	–	Sell	-1	Closed	-$18	–	7591
2023 Q1	$14	Hold	1	–	–	﹤0.01%	7598
2022 Q4	$11	Buy	+1	New	+$18	﹤0.01%	8072
2022 Q3	–	Hold	0	–	–	–	8197
2022 Q2	–	Hold	0	–	–	–	8384
2022 Q1	–	Sell	-1	Closed	-$68	–	8761
2021 Q4	$0	Sell	1 -2	-67%	-$189	﹤0.01%	8638
2021 Q3	$0	Buy	+3	New	+$373	﹤0.01%	8395
2021 Q2	–	Hold	0	–	–	–	8088
2021 Q1	–	Hold	0	–	–	–	7771
2020 Q4	–	Hold	0	–	–	–	7368
2020 Q3	–	Hold	0	–	–	–	7175
2020 Q2	–	Hold	0	–	–	–	7131
2020 Q1	–	Hold	0	–	–	–	7245
2019 Q4	–	Hold	0	–	–	–	7396
2019 Q3	–	Sell	-1	Closed	-$121	–	7502
2019 Q2	$0	Hold	1	–	–	﹤0.01%	7412
2019 Q1	$0	Hold	1	–	–	﹤0.01%	7408
2018 Q4	$0	Sell	1 -1	-50%	-$237	﹤0.01%	7383
2018 Q3	$1K	Sell	2 -1	-33%	-$1.1K	﹤0.01%	7153
2018 Q2	$5K	Buy	3 +1	+50%	+$2.3K	﹤0.01%	6801
2018 Q1	$5K	Hold	2	–	–	﹤0.01%	6770
2017 Q4	$8K	Hold	2	–	–	﹤0.01%	6665
2017 Q3	$17K	Hold	2	–	–	﹤0.01%	6340
2017 Q2	$9K	Sell	2 -2	-50%	-$9.96K	﹤0.01%	6462
2017 Q1	$19K	Buy	4 +1	+33%	+$6.98K	﹤0.01%	6333
2016 Q4	$22K	Buy	3 +1	+50%	+$10.3K	﹤0.01%	6314
2016 Q3	$26K	Buy	2 +1	+100%	+$15K	﹤0.01%	6023
2016 Q2	$10K	Buy	+1	New	+$18.8K	﹤0.01%	6501
2016 Q1	–	Sell	-1	Closed	-$15K	–	6397
2015 Q4	$29K	Hold	1	–	–	﹤0.01%	6281
2015 Q3	$29K	Hold	1	–	–	﹤0.01%	6186
2015 Q2	$36K	Sell	1 -1	-50%	-$20.1K	﹤0.01%	6098
2015 Q1	$32K	Buy	2 +1	+100%	+$17.9K	﹤0.01%	5851
2014 Q4	$9K	Sell	1 -21	-95%	-$282K	﹤0.01%	7108
2014 Q3	$342K	Sell	22 -2	-8%	-$32.5K	﹤0.01%	4923
2014 Q2	$357K	Sell	24 -1	-4%	-$15.9K	﹤0.01%	4957
2014 Q1	$553K	Sell	25 -2	-7%	-$41.4K	﹤0.01%	4501
2013 Q4	$356K	Hold	27	–	–	﹤0.01%	5069
2013 Q3	$400K	Hold	27	–	–	﹤0.01%	4829
2013 Q2	$411K	Buy	+27	New	+$369K	﹤0.01%	4933

Other funds holding TOVX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bank of America's TOVX Position: Q1 2026 in Review

Bank of America sold out of Theriva Biologics (TOVX) in Q1 2026, closing a stake of 31,139 shares — an estimated $6.54K sold.

Bank of America first reported a position in TOVX in Q2 2013 and held it in 35 quarters. The position peaked at $553K in Q1 2014. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

Bank of America reported no remaining Theriva Biologics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 31,139 Theriva Biologics shares in Q1 2026, an estimated $6.54K.
Bank of America first reported a position in Theriva Biologics in Q2 2013 and held it in 35 quarters.
Bank of America's Theriva Biologics position peaked at $553K in Q1 2014.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.